Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tango Therapeutics ( (TNGX) ) has issued an update.
On August 21, 2025, Douglas Barry announced his resignation as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics, effective September 12, 2025, to pursue another opportunity. This change in leadership may impact Tango Therapeutics’ operations and strategic direction as they adjust to the departure of a key executive.
The most recent analyst rating on (TNGX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including declining revenues and persistent losses. While technical analysis shows positive momentum, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Average Trading Volume: 2,667,200
Technical Sentiment Signal: Buy
Current Market Cap: $767.7M
For a thorough assessment of TNGX stock, go to TipRanks’ Stock Analysis page.